Transcutaneous Auricular Vagus Nerve Stimulation for Meniere Disease

Capital Medical University

Status: Completed

Conditions: Meniere Disease

Treatments: Drug: Betahistine Mesylate tablet; Device: taVNS

Study type: Observational

Funder types: Other

Identifiers

NCT06544590

taVNS-MD-2024

Details and patient eligibility

About

Objective: To evaluate the effect of Transcutaneous auricular vagus nerve stimulation for the patients Meniere disease.

Methods: We enrolled 231 patients at Beijing TongRen Hospital. All treatments were self-administered by the patients at home after training at the hospital. Patients completed questionnaires at baseline, 3 months, 6 months, and 12 months. Video head impulse test (VHIT), the caloric test, Tinnitus Handicap Inventory (THI), Dizziness Handicap Inventory (DHI), Pure Tone Audiometry, and visual scale of ear stuffiness to evaluate the therapeutic effects. A difference of P < 0.05 was considered statistically significant.

Enrollment: 77 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 1. Age >=18 and Age <=65. 2. Clinical diagnosis of meniere disease.

Exclusion criteria

1. History of depression, tumors, thyroid disease, diabetes, cardiac diseases.
2. History of Otorhinolaryngology surgery.
3. Pregnant or lactating women.

Trial design

77 participants in 3 patient groups

Control group

Treatment:

Drug: Betahistine Mesylate tablet

taVNS group

Treatment:

Drug: Betahistine Mesylate tablet

Device: taVNS

sham taVNS group

Treatment:

Drug: Betahistine Mesylate tablet

Device: taVNS